Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 05, 2023 08:00 ET | Source: QSAM Biosciences Inc.

QSAM Biosciences Opens Enrollment of the Second Cohort of Patients in its Phase 1 Study of CycloSam® Targeting Metastatic Bone Cancer

Austin, TX, April 05, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...
May 17, 2022 08:00 ET | Source: QSAM Biosciences Inc.

QSAM Biosciences Reports First Quarter 2022 Financial Results and Provides Corporate Update

Dosed First Patient in Phase 1 Clinical Program Evaluating CycloSam® Radiopharmaceutical Drug Candidate for Treatment of Metastatic Bone Cancer Austin, TX, May 17, 2022 (GLOBE NEWSWIRE) -- QSAM...
August 25, 2021 09:00 ET | Source: QSAM Biosciences Inc.

QSAM Biosciences Announces FDA Clearance of IND for Samarium-153 DOTMP (CycloSam®), an Investigational Radiopharmaceutical for the Treatment of Bone Cancer

Austin, TX, Aug. 25, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation nuclear medicines, including Samarium-153 DOTMP (CycloSam®), for the treatment...